TLR9 Expression and Prognosis in Renal Cell Carcinoma
Author Information
Author(s): Hanna Ronkainen, Pasi Hirvikoski, Saila Kauppila, Katri S. Vuopala, Timo K. Paavonen, Katri S. Selander, Markku H. Vaarala
Primary Institution: Oulu University Hospital
Hypothesis
The study aims to examine the expression of TLR9 in renal cell carcinoma and evaluate its prognostic value.
Conclusion
TLR9 expression is an independent prognostic marker of renal cell carcinoma, with its absence indicating poorer prognosis.
Supporting Evidence
- 81% of tumors exhibited cytoplasmic TLR9 immunostaining.
- Cytoplasmic TLR9 expression was associated with better RCC-specific survival.
- The mean survival time for TLR9 negative tumors was significantly shorter.
Takeaway
This study found that if a kidney cancer tumor has TLR9, patients tend to do better, but if it doesn't, they might not live as long.
Methodology
The study used immunohistochemistry to analyze TLR9 expression in tumor samples from 152 patients with renal cell carcinoma.
Participant Demographics
The cohort consisted of 152 patients, with 51% females and 49% males, median age 63 years.
Statistical Information
P-Value
0.007
Confidence Interval
95% CI 1.24-4.63
Statistical Significance
p = 0.007
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website